Skip to main content
. 2015 Sep 2;20(10):1132–1139. doi: 10.1634/theoncologist.2015-0156

Figure 4.

Figure 4.

Response after 3 months of trastuzumab in a 70-year-old patient with ERBB2 amplified esophageal adenocarcinoma identified by comprehensive genomic profiling. From left to right, extensive hepatic metastases (A) resolved after 3 months of genotype-directed therapy (B).